Clinical Study

B9991040- A Phase 1B/2 Study To Evaluate Safety And Clinical Activity Of Avelumab In Combination With Bempegaldesleukin (Nktr-214) With Or Without Talazoparib Or Enzalutamide In Participants With Locally Advanced Or Metastatic Solid Tumor

Posted Date: Apr 23, 2020

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal for phase 1 is To assess the dose-limiting toxicity (DLT) rate of avelumab in combination with bempegaldesleukin (NKTR-214) and talazoparib or enzalutamide in order to determine the recommended Phase 2 dose (RP2D) for the combinations.


To Be Eligible: Must Have Diagnosis Of Solid Tumor, Progressive Disease At Time Of Enrollment, Adequate Organ Function, No Prior Treatment For Study Cancer


Phase 1, Oncology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.